Uncheck anything you already have
Lancet Lond Engl 394:121130 Frias JP, Nauck MA, Van J, Benson C, Bray R, Cui X, Milicevic Z, Urva S, Haupt A, Robins DA (2020) Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens
Consequently, once-daily subcutaneous administration of liraglutide 3.0 mg was developed for the treatment of obesity [21] and once-weekly subcutaneous administration of semaglutide 2.4 mg is currently being investigated in phase III trials for this indication [22]
However, evidence-based ballparks include: Patients taking Wegovy (a semaglutide) for up to 68 weeks lost up to 12.4% of initial body weight
For Hashimoto's patients exploring GLP-1 options, having reliable, evidence-based resources is the difference between informed decision-making and risky guesswork
Ideally, stabilize on a dose for 4 weeks, then test the timing change for 4 additional weeks
